Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection

Eun Hye Lee, youngae kang, Ah Young Leem, Moo Suk Park, Young Sam Kim, Se Kyu Kim, Joon Chang, Song Yee Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

This study aimed to determine the incidence and characteristics of active tuberculosis (TB) in patients treated with tumor necrosis factor (TNF) antagonists according to baseline latent tuberculosis infection (LTBI). Data were retrospectively obtained from 702 patients aged ≥20 years treated with TNF antagonists between November 2005 and June 2016 at Severance Hospital, a tertiary referral hospital in Seoul, South Korea. The interferon-gamma release assay (IGRA) with or without a tuberculin skin test (TST) was used to diagnose LTBI. Of the total of 702 patients, LTBI was diagnosed in 255 (36.3%) patients. 23.9% (168/702) had positive IGRA results, and 32.2% (165/512) had positive TST results. Five patients developed active TB after LTBI treatment, and 6 developed TB despite baseline negative LTBI results. After adjustment for age and sex, the standardized TB incidence ratio was 6.01 (95% CI 1.94-14.04) in the LTBI group and 5.14 (95% CI 1.88-11.18) in the baseline negative LTBI group. Clinicians should be aware of the risk of active TB in patients treated with TNF antagonists despite baseline negative LTBI screening results. Regular monitoring and serial tests should be considered during long-term TNF antagonist therapy, especially in intermediate to high TB burden country.

Original languageEnglish
Article number6473
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Latent Tuberculosis
Tuberculosis
Tumor Necrosis Factor-alpha
Incidence
Interferon-gamma Release Tests
Tuberculin Test
Skin Tests
Republic of Korea
Tertiary Care Centers

All Science Journal Classification (ASJC) codes

  • General

Cite this

Lee, Eun Hye ; kang, youngae ; Leem, Ah Young ; Park, Moo Suk ; Kim, Young Sam ; Kim, Se Kyu ; Chang, Joon ; Kim, Song Yee. / Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{74a3ef03be6c4582ad6c59032d56c87a,
title = "Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection",
abstract = "This study aimed to determine the incidence and characteristics of active tuberculosis (TB) in patients treated with tumor necrosis factor (TNF) antagonists according to baseline latent tuberculosis infection (LTBI). Data were retrospectively obtained from 702 patients aged ≥20 years treated with TNF antagonists between November 2005 and June 2016 at Severance Hospital, a tertiary referral hospital in Seoul, South Korea. The interferon-gamma release assay (IGRA) with or without a tuberculin skin test (TST) was used to diagnose LTBI. Of the total of 702 patients, LTBI was diagnosed in 255 (36.3{\%}) patients. 23.9{\%} (168/702) had positive IGRA results, and 32.2{\%} (165/512) had positive TST results. Five patients developed active TB after LTBI treatment, and 6 developed TB despite baseline negative LTBI results. After adjustment for age and sex, the standardized TB incidence ratio was 6.01 (95{\%} CI 1.94-14.04) in the LTBI group and 5.14 (95{\%} CI 1.88-11.18) in the baseline negative LTBI group. Clinicians should be aware of the risk of active TB in patients treated with TNF antagonists despite baseline negative LTBI screening results. Regular monitoring and serial tests should be considered during long-term TNF antagonist therapy, especially in intermediate to high TB burden country.",
author = "Lee, {Eun Hye} and youngae kang and Leem, {Ah Young} and Park, {Moo Suk} and Kim, {Young Sam} and Kim, {Se Kyu} and Joon Chang and Kim, {Song Yee}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-06899-1",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection. / Lee, Eun Hye; kang, youngae; Leem, Ah Young; Park, Moo Suk; Kim, Young Sam; Kim, Se Kyu; Chang, Joon; Kim, Song Yee.

In: Scientific Reports, Vol. 7, No. 1, 6473, 01.12.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection

AU - Lee, Eun Hye

AU - kang, youngae

AU - Leem, Ah Young

AU - Park, Moo Suk

AU - Kim, Young Sam

AU - Kim, Se Kyu

AU - Chang, Joon

AU - Kim, Song Yee

PY - 2017/12/1

Y1 - 2017/12/1

N2 - This study aimed to determine the incidence and characteristics of active tuberculosis (TB) in patients treated with tumor necrosis factor (TNF) antagonists according to baseline latent tuberculosis infection (LTBI). Data were retrospectively obtained from 702 patients aged ≥20 years treated with TNF antagonists between November 2005 and June 2016 at Severance Hospital, a tertiary referral hospital in Seoul, South Korea. The interferon-gamma release assay (IGRA) with or without a tuberculin skin test (TST) was used to diagnose LTBI. Of the total of 702 patients, LTBI was diagnosed in 255 (36.3%) patients. 23.9% (168/702) had positive IGRA results, and 32.2% (165/512) had positive TST results. Five patients developed active TB after LTBI treatment, and 6 developed TB despite baseline negative LTBI results. After adjustment for age and sex, the standardized TB incidence ratio was 6.01 (95% CI 1.94-14.04) in the LTBI group and 5.14 (95% CI 1.88-11.18) in the baseline negative LTBI group. Clinicians should be aware of the risk of active TB in patients treated with TNF antagonists despite baseline negative LTBI screening results. Regular monitoring and serial tests should be considered during long-term TNF antagonist therapy, especially in intermediate to high TB burden country.

AB - This study aimed to determine the incidence and characteristics of active tuberculosis (TB) in patients treated with tumor necrosis factor (TNF) antagonists according to baseline latent tuberculosis infection (LTBI). Data were retrospectively obtained from 702 patients aged ≥20 years treated with TNF antagonists between November 2005 and June 2016 at Severance Hospital, a tertiary referral hospital in Seoul, South Korea. The interferon-gamma release assay (IGRA) with or without a tuberculin skin test (TST) was used to diagnose LTBI. Of the total of 702 patients, LTBI was diagnosed in 255 (36.3%) patients. 23.9% (168/702) had positive IGRA results, and 32.2% (165/512) had positive TST results. Five patients developed active TB after LTBI treatment, and 6 developed TB despite baseline negative LTBI results. After adjustment for age and sex, the standardized TB incidence ratio was 6.01 (95% CI 1.94-14.04) in the LTBI group and 5.14 (95% CI 1.88-11.18) in the baseline negative LTBI group. Clinicians should be aware of the risk of active TB in patients treated with TNF antagonists despite baseline negative LTBI screening results. Regular monitoring and serial tests should be considered during long-term TNF antagonist therapy, especially in intermediate to high TB burden country.

UR - http://www.scopus.com/inward/record.url?scp=85026268656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026268656&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-06899-1

DO - 10.1038/s41598-017-06899-1

M3 - Article

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 6473

ER -